Harie
Experienced Member
- Reaction score
- 5
Sort of strange that I didn't see this posted here too.
Copied from Moximus @ HLH
Silencing the androgen receptor: new skills for antiandrogen oligonucleotide skin and hair therapy.
Dugour A, Hagelin K, Smus C, Balañá ME, Kerner N.
http://uploading.com/files/MCVIRZMD/AR.pdf.html
------------------------------------------------------------------------------------------------
This group was able to transfect dermal papilla cells with anti sense anti androgen nucleotides they call ASAO 18.1. In cultures stimulated with DHT they were able to obtain 100% transfection efficience and 100% AR function inhibition. IMO that is unreal, although it would be nice to be tested further.
Unfortunately it is only a letter to the editor and very vague, but promising. A very complicated read though.
------------------------------------------------------------------------------------------------
http://www.nature.com/jid/jour.../n5/full/5602805a.html
Antisense oligodeoxynucleotides formulated in cream preparations are being examined in the clinic as topical therapy for psoriasis. To produce their intended anti-inflammatory effects, these large anionic molecules must penetrate the stratum corneum and reach the living epidermis and dermis. A topically applied phosphorothioate antisense oligonucleotide targeted to intercellular adhesion molecule-1 recently was shown to modulate cytokine-inducible target gene expression in engrafted human skin. In this study, we examined the route of entry into mouse skin of fluorochrome-tagged or naked second-generation 2'-O-methoxyethyl-modified oligonucleotides that react specifically with an antibody, using topical cream-based formulations. In hairless mouse skin, immunohistochemical analysis and fluorescence microscopy were unable to detect the presence of oligonucleotide in the epidermis or dermis following topical application although immunostaining was associated with the stratum corneum
Copied from Moximus @ HLH
Silencing the androgen receptor: new skills for antiandrogen oligonucleotide skin and hair therapy.
Dugour A, Hagelin K, Smus C, Balañá ME, Kerner N.
http://uploading.com/files/MCVIRZMD/AR.pdf.html
------------------------------------------------------------------------------------------------
This group was able to transfect dermal papilla cells with anti sense anti androgen nucleotides they call ASAO 18.1. In cultures stimulated with DHT they were able to obtain 100% transfection efficience and 100% AR function inhibition. IMO that is unreal, although it would be nice to be tested further.
Unfortunately it is only a letter to the editor and very vague, but promising. A very complicated read though.
------------------------------------------------------------------------------------------------
http://www.nature.com/jid/jour.../n5/full/5602805a.html
Antisense oligodeoxynucleotides formulated in cream preparations are being examined in the clinic as topical therapy for psoriasis. To produce their intended anti-inflammatory effects, these large anionic molecules must penetrate the stratum corneum and reach the living epidermis and dermis. A topically applied phosphorothioate antisense oligonucleotide targeted to intercellular adhesion molecule-1 recently was shown to modulate cytokine-inducible target gene expression in engrafted human skin. In this study, we examined the route of entry into mouse skin of fluorochrome-tagged or naked second-generation 2'-O-methoxyethyl-modified oligonucleotides that react specifically with an antibody, using topical cream-based formulations. In hairless mouse skin, immunohistochemical analysis and fluorescence microscopy were unable to detect the presence of oligonucleotide in the epidermis or dermis following topical application although immunostaining was associated with the stratum corneum